tiprankstipranks
Pacific Biosciences (PACB)
NASDAQ:PACB
US Market
PACB
Pacific Biosciences
RESEARCH TOOLSreports
Want to see PACB full AI Analyst Report?

Pacific Biosciences (PACB) Stock Forecast & Price Target

2,872 Followers
See the Price Targets and Ratings of:

PACB Analyst Ratings

Hold
4Ratings
Hold
2 Buy
1 Hold
1 Sell
Based on 4 analysts giving stock ratings to
Pacific
Biosciences
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

PACB Stock 12 Month Forecast

Average Price Target

$2.38
▲(40.53% Upside)
Based on 4 Wall Street analysts offering 12 month price targets for Pacific Biosciences in the last 3 months. The average price target is $2.38 with a high forecast of $3.00 and a low forecast of $1.50. The average price target represents a 40.53% change from the last price of $1.69.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","1":"$1","2":"$2","3":"$3","4":"$4"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.375,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1,2,3,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.74,1.8369230769230769,1.9338461538461538,2.0307692307692307,2.1276923076923078,2.2246153846153844,2.3215384615384616,2.418461538461538,2.5153846153846153,2.6123076923076924,2.709230769230769,2.8061538461538458,2.903076923076923,{"y":3,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.74,1.7888461538461538,1.8376923076923077,1.8865384615384615,1.9353846153846153,1.9842307692307692,2.0330769230769232,2.081923076923077,2.1307692307692307,2.1796153846153845,2.2284615384615383,2.2773076923076925,2.3261538461538462,{"y":2.375,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.74,1.7215384615384615,1.7030769230769232,1.6846153846153846,1.666153846153846,1.6476923076923078,1.6292307692307693,1.6107692307692307,1.5923076923076924,1.573846153846154,1.5553846153846154,1.536923076923077,1.5184615384615385,{"y":1.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.29,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.33,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.28,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.38,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.34,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.23,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.87,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.06,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.62,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.35,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.6,"date":1777593600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.58,"date":1780272000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.74,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$3.00Average Price Target$2.38Lowest Price Target$1.50
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on PACB
Luke Sergott
Barclays
Barclays
$1→$1.5
Sell
-11.24%
Downside
Assigned
05/11/26
Analysts Offer Insights on Healthcare Companies: Neuren Pharmaceuticals Limited (Other OTC: NURPF), Astrana Health (NASDAQ: ASTH) and Pacific Biosciences (NASDAQ: PACB)
TD Cowen Analyst forecast on PACB
Daniel Brennan
TD Cowen
TD Cowen
$3
Buy
77.51%
Upside
Reiterated
05/08/26
Analysts Are Bullish on Top Healthcare Stocks: Pacific Biosciences (PACB), 20/20 Biolabs, Inc. (AIDX)
Piper Sandler Analyst forecast on PACB
David Westenberg
Piper Sandler
Piper Sandler
$2
Hold
18.34%
Upside
Reiterated
05/08/26
Pacific Biosciences (PACB) Gets a Hold from Piper Sandler
Canaccord Genuity Analyst forecast on PACB
Kyle Mikson CFA
Canaccord Genuity
Canaccord Genuity
$3
Buy
77.51%
Upside
Reiterated
05/08/26
Canaccord Genuity Sticks to Its Buy Rating for Pacific Biosciences (PACB)
Guggenheim Analyst forecast on PACB
Subbu Nambi
Guggenheim
Guggenheim
―
Hold
―
Reiterated
02/12/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Tenet Healthcare (NYSE: THC) and Pacific Biosciences (NASDAQ: PACB)
Stephens Analyst forecast on PACB
Mason Carrico
Stephens
Stephens
$1.8→$2
Buy
18.34%
Upside
Reiterated
11/10/25
PacBio price target raised to $2 from $1.80 at StephensPacBio price target raised to $2 from $1.80 at Stephens
Bernstein Analyst forecast on PACB
Eve Burstein
Bernstein
Bernstein
$1.5→$1.7
Buy
0.59%
Upside
Reiterated
08/08/25
Pacific Biosciences (PACB) Gets a Buy from Bernstein
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on PACB
Luke Sergott
Barclays
Barclays
$1→$1.5
Sell
-11.24%
Downside
Assigned
05/11/26
Analysts Offer Insights on Healthcare Companies: Neuren Pharmaceuticals Limited (Other OTC: NURPF), Astrana Health (NASDAQ: ASTH) and Pacific Biosciences (NASDAQ: PACB)
TD Cowen Analyst forecast on PACB
Daniel Brennan
TD Cowen
TD Cowen
$3
Buy
77.51%
Upside
Reiterated
05/08/26
Analysts Are Bullish on Top Healthcare Stocks: Pacific Biosciences (PACB), 20/20 Biolabs, Inc. (AIDX)
Piper Sandler Analyst forecast on PACB
David Westenberg
Piper Sandler
Piper Sandler
$2
Hold
18.34%
Upside
Reiterated
05/08/26
Pacific Biosciences (PACB) Gets a Hold from Piper Sandler
Canaccord Genuity Analyst forecast on PACB
Kyle Mikson CFA
Canaccord Genuity
Canaccord Genuity
$3
Buy
77.51%
Upside
Reiterated
05/08/26
Canaccord Genuity Sticks to Its Buy Rating for Pacific Biosciences (PACB)
Guggenheim Analyst forecast on PACB
Subbu Nambi
Guggenheim
Guggenheim
―
Hold
―
Reiterated
02/12/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Tenet Healthcare (NYSE: THC) and Pacific Biosciences (NASDAQ: PACB)
Stephens Analyst forecast on PACB
Mason Carrico
Stephens
Stephens
$1.8→$2
Buy
18.34%
Upside
Reiterated
11/10/25
PacBio price target raised to $2 from $1.80 at StephensPacBio price target raised to $2 from $1.80 at Stephens
Bernstein Analyst forecast on PACB
Eve Burstein
Bernstein
Bernstein
$1.5→$1.7
Buy
0.59%
Upside
Reiterated
08/08/25
Pacific Biosciences (PACB) Gets a Buy from Bernstein
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Pacific Biosciences

3 Months
Daniel BrennanTD Cowen
Success Rate
11/20 ratings generated profit
55%
Average Return
+1.36%
Copying Daniel Brennan's trades and holding each position for 3 Months would result in 55.00% of your transactions generating a profit, with an average return of +1.36% per trade.
1 Year
Kyle Mikson CFACanaccord Genuity
Success Rate
10/28 ratings generated profit
36%
Average Return
+7.04%
Copying Kyle Mikson CFA's trades and holding each position for 1 Year would result in 35.71% of your transactions generating a profit, with an average return of +7.04% per trade.
2 Years
Daniel BrennanTD Cowen
Success Rate
10/20 ratings generated profit
50%
Average Return
-15.43%
Copying Daniel Brennan's trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of -15.43% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PACB Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
3
3
3
2
2
Buy
3
0
0
0
0
Hold
4
4
1
1
1
Sell
1
2
3
2
1
Strong Sell
0
0
0
0
0
total
11
9
7
5
4
In the current month, PACB has received 2 Buy Ratings, 1 Hold Ratings, and 1 Sell Ratings. PACB average Analyst price target in the past 3 months is 2.38.
Each month's total comprises the sum of three months' worth of ratings.

PACB Financial Forecast

PACB Earnings Forecast

Next quarter’s earnings estimate for PACB is -$0.13 with a range of -$0.15 to -$0.12. The previous quarter’s EPS was -$0.03. PACB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year PACB has Performed in-line its overall industry.
Next quarter’s earnings estimate for PACB is -$0.13 with a range of -$0.15 to -$0.12. The previous quarter’s EPS was -$0.03. PACB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year PACB has Performed in-line its overall industry.

PACB Sales Forecast

Next quarter’s sales forecast for PACB is $40.04M with a range of $38.70M to $40.91M. The previous quarter’s sales results were $37.18M. PACB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year PACB has Performed in-line its overall industry.
Next quarter’s sales forecast for PACB is $40.04M with a range of $38.70M to $40.91M. The previous quarter’s sales results were $37.18M. PACB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year PACB has Performed in-line its overall industry.

PACB Stock Forecast FAQ

What is PACB’s average 12-month price target, according to analysts?
Based on analyst ratings, Pacific Biosciences’s 12-month average price target is 2.38.
    What is PACB’s upside potential, based on the analysts’ average price target?
    Pacific Biosciences has 40.53% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is PACB a Buy, Sell or Hold?
          Pacific Biosciences has a consensus rating of Hold which is based on 2 buy ratings, 1 hold ratings and 1 sell ratings.
            What is Pacific Biosciences’s price target?
            The average price target for Pacific Biosciences is 2.38. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $3.00 ,the lowest forecast is $1.50. The average price target represents 40.53% Increase from the current price of $1.69.
              What do analysts say about Pacific Biosciences?
              Pacific Biosciences’s analyst rating consensus is a Hold. This is based on the ratings of 4 Wall Streets Analysts.
                How can I buy shares of PACB?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.